Form 4: Stereotaxis Director and 10% Owner Nathan Fischel Receives Significant RSU Grant

Nathan Fischel, a Director and 10% owner of Stereotaxis, Inc., was granted 43,668 restricted share units of common stock on July 1, 2025, increasing his total beneficial ownership.

Summary

• Nathan Fischel, a Director and 10% owner of Stereotaxis, Inc. (STXS), was granted 43,668 restricted share units (RSUs) of common stock on July 1, 2025.
• These RSUs were granted at a price of $0, indicating they are part of a compensation or incentive plan.
• Each restricted share unit represents a right to receive one share of common stock.
• The restricted share units will vest on the earliest to occur of: the fifth anniversary of the award date, the date on which the director's service on the board terminates, or a Change of Control as defined in the award documents.
• Following this transaction, Nathan Fischel's direct beneficial ownership of common stock is 630,724 shares.
• His indirect beneficial ownership is 13,680,554 shares, held by funds of which DAFNA Capital Management LLC is the investment manager and general partner, and Dr. Fischel is the Chief Executive Officer of DAFNA Capital Management, LLC.

Sentiment

Score: 7

Explanation: The grant of restricted share units to a director and 10% owner is generally a positive signal, indicating alignment of interests and confidence in the company's future. It's a standard compensation practice, not a direct indicator of operational performance, hence a moderately positive score.

Positives

• The grant of restricted share units to a director and significant owner aligns his interests with long-term shareholder value.
• The grant at a $0 price suggests an incentive-based compensation, potentially motivating continued strong performance.
• Increased beneficial ownership by a 10% owner can signal confidence in the company's future prospects.

Risks

• The ultimate value of the restricted share units is contingent on the future stock price of Stereotaxis, Inc., making them subject to market fluctuations.
• Vesting conditions, particularly the 'fifth anniversary' clause, mean the shares are not immediately liquid and their value is contingent on continued service or specific corporate events.

Future Outlook

The grant of restricted share units with future vesting conditions indicates a long-term incentive structure for the director, aligning his future compensation with the company's performance over the next five years or until a change of control or termination of service.

Industry Context

This Form 4 filing reflects a standard practice of granting equity compensation to directors, a common mechanism across industries to align leadership interests with shareholder value. For medical device companies like Stereotaxis, attracting and retaining experienced directors is crucial for strategic guidance and market positioning.

Comparison to Industry Standards

• Equity grants, such as Restricted Share Units (RSUs), are a common form of director compensation across publicly traded companies, including those in the medical technology sector, to incentivize long-term commitment and performance.
• The grant of 43,668 RSUs to a director and 10% owner like Nathan Fischel is a significant award, comparable to grants seen in similar-sized medical device companies aiming to retain key leadership and align interests.
• The vesting conditions (fifth anniversary, termination of service, or Change of Control) are standard for long-term incentive plans, ensuring the director's interests remain tied to the company's sustained success or a significant liquidity event.

Stakeholder Impact

• Shareholders: The grant of RSUs to a director and 10% owner aligns management's interests with shareholder value, potentially leading to better long-term performance.

Next Steps

• The restricted share units will vest on the earliest of the fifth anniversary of the award date, the termination of the director's service on the board, or a Change of Control.

Key Dates

Keywords

Stereotaxis, STXS, Nathan Fischel, Form 4, SEC filing, beneficial ownership, restricted share units, RSUs, insider transaction, director compensation, equity grant